AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

EyePoint Pharmaceuticals, Inc. Director's Dealing 2023

Feb 13, 2023

32254_dirs_2023-02-13_53537aed-fcc6-4ba8-ad95-5d23fd955174.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2023-02-09

Reporting Person: Elston George (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-09	Common Stock	M	5833.00	$0.00	Acquired	18149.00	Direct
2023-02-09	Common Stock	M	4967.00	$0.00	Acquired	23116.00	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-09	Restricted Stock Units	$0.00	M	5833.00	Disposed		Common Stock (5833.00)	Direct
2023-02-09	Restricted Stock Units	$0.00	M	4967.00	Disposed		Common Stock (4967.00)	Direct

Footnotes

F1: Includes 887 shares acquired on 7/31/22 and 2,745 shares acquired on January 31, 2023, pursuant to EyePoint's 2019 Employee Stock Purchase Plan.

F2: The restricted stock units vests in three ratable annual installments beginning February 9, 2023.